In yesterday’s Wall Street session, Boston Scientific Corp. (NYSE:BSX) shares traded at $56.48, up 0.95% from the previous session.
30 analysts cover Boston Scientific Corp. (NYSE:BSX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $67.00 and a low of $52.50, we find $61.00. Given the previous closing price of $55.95, this indicates a potential upside of 9.03 percent. BSX stock price is now 7.07% away from the 50-day moving average and 8.78% away from the 200-day moving average. The market capitalization of the company currently stands at $82.74B.
The stock has received a hold rating from 3 analysts and a buy rating from 21. Brokers who have rated the stock have averaged $60.98 as their price target over the next twelve months.
With the price target of $59, Robert W. Baird recently initiated with Outperform rating for Boston Scientific Corp. (NYSE: BSX).
In other news, Mirviss Jeffrey B., EVP&Pres, Periph Intervent sold 353 shares of the company’s stock on Dec 06. The stock was sold for $19,426 at an average price of $55.03. Upon completion of the transaction, the EVP&Pres, Periph Intervent now directly owns 56,588 shares in the company, valued at $3.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 20, EVP& Grp Pres, MedSurg & APAC Butcher Arthur C sold 8,278 shares of the business’s stock. A total of $447,509 was realized by selling the stock at an average price of $54.06. This leaves the insider owning 6,977 shares of the company worth $0.39 million. Insiders disposed of 1,355,997 shares of company stock worth roughly $76.59 million over the past 1 year. A total of 0.43% of the company’s stock is owned by insiders.
On Wednesday morning Boston Scientific Corp. (NYSE: BSX) stock kicked off with the opening price of $56.04. During the past 12 months, Boston Scientific Corp. has had a low of $44.35 and a high of $56.22. As of last week, the company has a debt-to-equity ratio of 0.49, a current ratio of 1.42, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $90.31B, which is based on a 69.18 price-to-earnings ratio, a 5.58 price-to-earnings-growth ratio, and a beta of 0.78. The fifty day moving average price for BSX is $52.75 and a two-hundred day moving average price translates $51.92 for the stock.
The latest earnings results from Boston Scientific Corp. (NYSE: BSX) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0.5, beating analysts’ expectations of $0.48 by 0.02. This compares to $0.13 EPS in the same period last year. The net profit margin was 8.66% and return on equity was 6.72% for BSX. The company reported revenue of $3.53 billion for the quarter, compared to $3.17 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.26 percent. For the current quarter, analysts expect BSX to generate $3.59B in revenue.
